The article text was unavailable because access to the page was denied, so its claims cannot be independently summarised in detail. Based on the headline, an FDA panel appears to have rejected one peptide-related product or proposal despite public or industry backlash.

This matters because FDA advisory-panel decisions can influence drug development, patient access and regulatory confidence. The available material does not identify the peptide, the panel’s reasoning, the vote, or the nature of the backlash.